Open AccessLenvatinib: A potent oral tyrosine kinase inhibitor across multiple histologies with differing dosages
Author(s) -
Bipinesh Sansar,
Neha Singh,
Avtar Singh
Publication year - 2022
Publication title -
cancer research, statistics, and treatment/cancer research, statistics and treatment
Language(s) - English
Resource type - Journals
eISSN - 2590-3233
pISSN - 2590-3225
DOI - 10.4103/crst.crst_31_22
Subject(s) - lenvatinib , tyrosine kinase inhibitor , pharmacology , medicine , tyrosine kinase , kinase , dose , oncology , chemistry , receptor , biochemistry , cancer , sorafenib , hepatocellular carcinoma